NASDAQ:DRUG Bright Minds Biosciences (DRUG) Stock Price, News & Analysis $19.95 -1.60 (-7.42%) As of 10:16 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bright Minds Biosciences Stock (NASDAQ:DRUG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DRUG alerts:Sign Up Key Stats Today's Range$20.74▼$22.4850-Day Range$21.55▼$79.4952-Week Range$18.90▼$123.75Volume37,233 shsAverage Volume212,406 shsMarket Capitalization$194.13 millionP/E RatioN/ADividend YieldN/APrice Target$126.29Consensus RatingModerate Buy Company Overview Bright Minds Biosciences Inc. is a biotechnology company focused on developing novel treatments for neurological and psychiatric disorders. The company’s research is centered on serotonergic compounds designed to provide therapeutic benefits associated with psychedelic medicines while potentially reducing unwanted effects such as hallucinations and cardiovascular or behavioral complications. Bright Minds’ pipeline includes BMB-101, a selective serotonin 5-HT2C receptor agonist being developed for conditions including substance use disorders. The company is also advancing additional investigational compounds that target serotonin receptors and are intended for potential use in disorders such as depression, addiction and other neuropsychiatric conditions. Its programs remain in the research and clinical-development stages, and its candidates have not necessarily received regulatory approval. Founded in Canada, Bright Minds Biosciences conducts biotechnology research and development for potential applications in international pharmaceutical markets. The company is headquartered in Vancouver, British Columbia, and is led by co-founder and Chief Executive Officer Ian McDonald.AI Generated. May Contain Errors. Read More Bright Minds Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreDRUG MarketRank™: 3.34853158106 of 5 starsBright Minds Biosciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 256th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingBright Minds Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 9 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialBright Minds Biosciences has a consensus price target of $126.29, representing about 486.0% upside from its current price of $21.55.Amount of Analyst CoverageBright Minds Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bright Minds Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Bright Minds Biosciences are expected to decrease in the coming year, from ($2.93) to ($6.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bright Minds Biosciences is -10.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bright Minds Biosciences is -10.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBright Minds Biosciences has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Bright Minds Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.87% of the float of Bright Minds Biosciences has been sold short.Short Interest Ratio / Days to CoverBright Minds Biosciences has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Bright Minds Biosciences has recently decreased by 6.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBright Minds Biosciences does not currently pay a dividend.Dividend GrowthBright Minds Biosciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.38 News SentimentBright Minds Biosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Bright Minds Biosciences this week, compared to 3 articles on an average week.Search Interest1 people have searched for DRUG on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Bright Minds Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bright Minds Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders42.66% of the stock of Bright Minds Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.52% of the stock of Bright Minds Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bright Minds Biosciences' insider trading history. Receive DRUG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bright Minds Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRUG Stock News HeadlinesFDA puts partial hold on Bright Minds’ Phase II seizure studyNovember 3 at 3:32 PM | msn.comBright Minds Biosciences: Downgrade To 'Hold' On BMB-101 Setback DEE And Progression Into PWSNovember 3 at 3:32 PM | seekingalpha.comFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.November 4 at 1:00 AM | Weiss Ratings (Ad)DRUG SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Bright Minds BiosciencesNovember 3 at 3:32 PM | prnewswire.comBright Minds Biosciences' BMB-101 Phase 2 Trial Placed on FDA Partial HoldNovember 3 at 4:31 AM | finance.yahoo.comBright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)November 2 at 6:26 PM | prnewswire.comFDA Places Bright Minds' Planned Phase 2 BMB-101 Study On Partial Clinical Hold; Stock PlungesNovember 2 at 1:30 PM | rttnews.comBright Minds stock plunges as FDA halts epilepsy trialNovember 2 at 1:30 PM | finance.yahoo.comSee More Headlines DRUG Stock Analysis - Frequently Asked Questions How have DRUG shares performed this year? Bright Minds Biosciences' stock was trading at $78.04 at the beginning of 2026. Since then, DRUG shares have decreased by 72.4% and is now trading at $21.55. How were Bright Minds Biosciences' earnings last quarter? Bright Minds Biosciences Inc. (NASDAQ:DRUG) posted its quarterly earnings data on Friday, August, 14th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $1.05. When did Bright Minds Biosciences' stock split? Bright Minds Biosciences's stock reverse split on Friday, July 14th 2023.The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Bright Minds Biosciences? Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bright Minds Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bright Minds Biosciences investors own include NVIDIA (NVDA), Rigetti Computing (RGTI), IonQ (IONQ), Archer Aviation (ACHR), Palantir Technologies (PLTR), SoundHound AI (SOUN) and Tesla (TSLA). Company Calendar Last Earnings8/14/2026Today11/04/2026Next Earnings (Estimated)12/22/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 2 days ago, DRUG's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:DRUG CIK1827401 Webbrightmindsbio.com Phone64-7407-2515FaxN/AEmployees25Year Founded2019Price Target and Rating Average Price Target for Bright Minds Biosciences$126.29 High Price Target$220.00 Low Price Target$37.00 Potential Upside/Downside+532.9%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($2.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-12.46% Return on Assets-12.30% Debt Debt-to-Equity RatioN/A Current Ratio122.00 Quick Ratio122.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.33 per share Price / Book2.40Miscellaneous Outstanding Shares9,730,000Free Float5,580,000Market Cap$194.13 million OptionableOptionable Beta-5.11 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:DRUG) was last updated on 11/4/2026 by MarketBeat.com Staff. From Our PartnersDr. Ron Paul: “It’s time to prepare”The Pentagon has plans for military bases to survive a 90-day disaster. A former Defense Intelligence Agency s...Stansberry Research | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe IPO wave is here and I'm getting paid monthlySpaceX, Anthropic, and OpenAI are leading a new wave of blockbuster IPOs. Tim Plaehn found a quiet fund that l...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bright Minds Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bright Minds Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRUG Stock Alerts